ABBV-621 + FOLFIRI + bevacizumab

ABBV-621 + FOLFIRI + bevacizumab is an investigational multi-drug combination regimen being evaluated primarily for metastatic or previously-treated colorectal cancer, particularly in RAS-mutant subpopulations. The regimen consists of: - **ABBV-621 (eftozanermin alfa)**, a second-generation TRAIL receptor agonist (recombinant fusion protein) that binds to the death receptors DR4 and DR5 on tumor cells, inducing apoptosis via caspase-dependent pathways. - **FOLFIRI**, a standard chemotherapy regimen composed of three drugs: irinotecan (topoisomerase I inhibitor), fluorouracil (5-FU, a pyrimidine antimetabolite), and folinic acid (leucovorin, enhances 5-FU activity). - **Bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis. The combination is delivered intravenously and is under investigation for its safety, tolerability, and preliminary antitumor activity in colorectal cancer, with additional interest in solid tumors. ABBV-621 is developed by AbbVie, and the broader regimen may involve manufacturers of the constituent drugs[3][5][2].

Other names

eftozanermin alfa + FOLFIRI + bevacizumab